Medincell wins milestone from Teva on back of SOLARIS trial

10 February 2025

France-based biopharma company Medincell (Euronext: MEDCL) this morning revealed it is to receive a $5 million development milestone from Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) as the SOLARIS study completed.

The pivotal clinical Phase III trial for the olanzapine long-acting injectable (LAI) in schizophrenia (SOLARIS) has been completed, following the final visit of the last patient in the 48 weeks open-label safety period, according to Teva, which finances and pilots the regulatory development of the product (mdc-TJK / TEV-'749).

Despite the positive news, Medincell’s shares were down 2.5% at 15.40 euros by late morning.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical